Importance of prompt recognition of infections during treatment with ribociclib to prevent serious infectious complications [1]
IMPORTANCE OF PROMPT RECOGNITION OF INFECTIONS DURING TREATMENT WITH RIBOCICLIB TO PREVENT SERIOUS INFECTIOUS COMPLICATIONS
The patient had left modified radical mastectomy at the age of 51 due to breast cancer:
- invasive ductal carcinoma, 4,5 cm large, grade III, ER 100%, PR 95%, MIB-1 20%, HER2 status negative,
- 7/28 lymph nodes positive,
- genetic testing negative, PIK3CA mutation not found in the primary tumor,
- adjuvant treatment: chemotherapy with anthracyclines and taxanes, radiation therapy and tamoxifen.
She relapsed after 16 months of adjuvant tamoxifen treatment with bone metastases and was treated in 1st line with ribociclib and letrozole:
- She remained progression free for almost 4 years
- She suffered one serious adverse event: erysipelas with sepsis due to delayed consultation of the doctor after the injury to her finger during gardening.
She is now on her 3rd line of treatment, fully active with good quality of life.